学科与关键词
关键词
NSCLCEGFR-TKIschemotherapy
- Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung AdenocarcinomaZhang, C.; Zhang, S.; Yao, Y.; Gao, Y.; Huang, J.; Peng, K.; Gao, Q.; Chen, H.; Xu, C.; Zhang, X.; Wu, Y.; Yang, J.被引 3
- ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC PatientsFeng, W.; Gu, W.; Zhang, H.; Lu, Y.; Gu, W.; Li, M.; Yang, S.; Ye, Z.; Liu, J.; Lin, Q.; Liang, Y.; Zhang, J.; Chen, H.; Shi, X.; Wang, F.; You, D.
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatmentYuman, Yu; Yuehong, Wang; Linying, Wu; Xuanli, Xu; Hua, Zhou; Qing, Wang; Jianying, ZhouMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23712.
